Orion Corporation: Managers’ transactions – Veli-Matti Mattila
22 Abril 2024 - 1:45AM
Orion Corporation: Managers’ transactions – Veli-Matti Mattila
ORION CORPORATION MANAGERS’ TRANSACTIONS 22 APRIL 2024 at 9.45
EEST
Orion Corporation: Managers’ transactions – Veli-Matti
Mattila
Orion Corporation has received the following disclosure under
Market Abuse Regulation (EU) No 596/2014, regarding transactions
with shares and linked securities in Orion Corporation made by
managers and their closely associated persons.
Orion Oyj - Managers'
Transactions____________________________________________Person
subject to the notification requirementName: Veli-Matti
MattilaPosition: Member of the Board/Deputy member Issuer: Orion
OyjLEI: 74370029VAHCXDR7B745Notification type: INITIAL
NOTIFICATIONReference number: 59158/6/8
____________________________________________Transaction date:
2024-04-19Outside a trading venueInstrument type: SHAREISIN:
FI0009014369Nature of transaction: GIFT,DONATION OR INHERITANCE
(RECEIVED)
Transaction details(1): Volume: 460 Unit price: 0 EUR
Aggregated transactions (1): Volume: 460 Volume weighted average
price: 0 EUR____________________________________________Transaction
date: 2024-04-19Outside a trading venueInstrument type: SHAREISIN:
FI0009014377Nature of transaction: GIFT,DONATION OR INHERITANCE
(RECEIVED)
Transaction details(1): Volume: 386 Unit price: 0 EUR
Aggregated transactions (1): Volume: 386 Volume weighted average
price: 0 EUR
Orion Corporation
| Liisa
HurmePresident and CEO |
|
Olli HuotariSVP,
Corporate Functions |
|
Publisher:Orion
CorporationCommunicationsOrionintie 1A, FI-02200 Espoo,
Finlandhttp://www.orion.fi/enhttp://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company – a
builder of well-being. We develop, manufacture and market human and
veterinary pharmaceuticals and active pharmaceutical ingredients.
Orion has an extensive portfolio of proprietary and generic
medicines and consumer health products. The core therapy areas of
our pharmaceutical R&D are oncology and pain. Proprietary
products developed by Orion are used to treat cancer, neurological
diseases and respiratory diseases, among others. Orion's net sales
in 2023 amounted to EUR 1,190 million and the company had about
3,600 employees at the end of the year. Orion's A and B shares are
listed on Nasdaq Helsinki.
Orion (BIT:1ORNBV)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Orion (BIT:1ORNBV)
Gráfica de Acción Histórica
De May 2023 a May 2024
